Company Filing History:
1 out of 1 
1 out of 2 Years Active: 1992-1998
Title: Claude Clement: Innovator in Monoclonal Antibody Development
Introduction
Claude Clement, an accomplished inventor based in Gray, France, has made significant contributions to the field of biotechnology. With a total of two patented inventions, he has focused primarily on the development of monoclonal antibodies with therapeutic applications.
Latest Patents
Claude’s most recent innovations include the development of anti-gp130 monoclonal antibodies. This invention encompasses antibodies that are crucial for creating medicinal products and diagnostic reagents. His second notable patent pertains to a specific monoclonal murine-IgG1 antibody derived from a new hybridoma cell line. This antibody binds to a unique epitope of the human interleukin-2 receptor, differing from the well-known Tac. Such antibodies have the potential to inhibit the binding of human interleukin-2 to its receptor, proving beneficial for the treatment and prevention of interleukin-2-dependent diseases in humans.
Career Highlights
Throughout his career, Claude Clement has collaborated with esteemed organizations such as Diaclone S.A. and the Centre Regional De Transfusion Sanguine. These affiliations have enabled him to focus on his research and contribute to advancements in medical science through his patents.
Collaborations
Claude has worked alongside notable colleagues, including John Wijdenes and Patrick Herve. Their combined expertise has undoubtedly helped foster an environment of innovation and success in the projects they undertook.
Conclusion
Claude Clement stands out as a forward-thinking inventor whose work in monoclonal antibodies holds significant promise for medical therapies. His patents underscore his commitment to scientific advancement and his impact on the field of biotechnology.